The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies

Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of seventh biannual meeting (March 2015)

(2015)   MALARIA JOURNAL

Optimum population-level use of artemisinin combination therapies: a modelling study

(2015) Tran Dang Nguyen et al.   Lancet Global Health

Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach

(2012) Tiago Antao et al.   MALARIA JOURNAL

Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases?

(2011) COLIN J. SUTHERLAND et al.   PARASITOLOGY

Similar Efficacy and Tolerability of Double-Dose Chloroquine and Artemether-Lumefantrine for Treatment of Plasmodium falciparum Infection in Guinea-Bissau: A Randomized Trial

(2010) Johan Ursing et al.   JOURNAL OF INFECTIOUS DISEASES

Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty

(2010) David L Smith et al.   MALARIA JOURNAL

Cost is killing patients: subsidising effective antimalarials

(2009) Ambrose Talisuna et al.   LANCET

Artemisinin Resistance inPlasmodium falciparumMalaria

(2009) Arjen M. Dondorp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment

(2009) Verena Ilona Carrara et al.   PLoS One

Piloting the Global Subsidy: The Impact of Subsidized Artemisinin-Based Combination Therapies Distributed through Private Drug Shops in Rural Tanzania

(2009) Oliver J. Sabot et al.   PLoS One

Benefits of using multiple first-line therapies against malaria

(2008) M. F. Boni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA